<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376477</url>
  </required_header>
  <id_info>
    <org_study_id>J16118</org_study_id>
    <secondary_id>IRB00112179</secondary_id>
    <nct_id>NCT03376477</nct_id>
  </id_info>
  <brief_title>Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide Compared to Lenalidomide Alone in Multiple Myeloma Patients</brief_title>
  <official_title>Randomized Phase II Trial of an Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide Compared to Lenalidomide Alone in Multiple Myeloma Patients in Complete or Near Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aduro Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's primary objective is to compare the 2-year progression free survival of
      patients treated with lenalidomide alone or in combination with vaccine
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">October 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 16, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to receive either lenalidomide alone or in combination with vaccine. Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. All patients will be followed for a minimum of 3 years.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>• To compare the 2-year progression free survival of patients treated with lenalidomide alone or in combination with vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR Conversion Rate</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the rate of conversion from near CR (immunofixation positive) to true CR (immunofixation negative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD Conversion Rate</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the rate of conversion from MRD (Minimal Residual Disease) positive status to MRD negative status by NGS (next generation sequencing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Determine progression free survival at 3 and 5 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide plus GM-CSF Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.
Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenalidomide Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GM-CSF vaccine</intervention_name>
    <description>Each vaccination will consist of three total intra-dermal injections, one each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injections sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.3-0.4ml.</description>
    <arm_group_label>Lenalidomide plus GM-CSF Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).</description>
    <arm_group_label>Lenalidomide plus GM-CSF Vaccine</arm_group_label>
    <arm_group_label>Lenalidomide Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myeloma eligibility criteria are the following:

          -  Near complete remission (nCR) for ≥ 3 months defined as no measurable M-spike, and a
             positive serum immunofixation

          -  Or complete remission (CR) (no measurable M-spike, immunofixation negative and bone
             marrow plasma cells &lt;5%)

          -  NDMM or RMM in nCR or CR having completed a minimum of 6 cycles of a lenalidomide
             based regimen for a minimum of ≥ 3 months

          -  NDMM or RMM a patients who have been off corticosteroids for ≥ 4 weeks

          -  Patients with NDMM or RMM who have had autologous stem cell transplant are eligible,
             but must be ≥ 12 months from transplant

          -  Age &gt;18 years

          -  ECOG performance scores 0-2

          -  History of measurable serum or urine M protein or free light chains

          -  Life expectancy greater than 12 months

          -  Corrected serum calcium &lt; 11 mg/dL, and no evidence of symptomatic hypercalcemia

          -  Serum creatinine&lt; 2 mg/dl

          -  ANC &gt;1000/µL

          -  Platelet &gt;100,000/µL

          -  Total bilirubin &lt;= 1.5 x ULN

          -  AST (SGOT) and ALT (SGPT) &lt;= 3 x ULN.

          -  Ability to comprehend and have signed the informed consent.

          -  Have previously agreed to continue on maintenance therapy with lenalidomide concurrent
             with vaccine administration until disease progression, or clinical indication to cease
             therapy.

          -  Disease free of prior malignancies for at least 5 years with exception of currently
             treated basal cell or squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of
             the uterus, cervix or breast.

          -  All study participants must be registered into the mandatory Revlimid REMS® program,
             and be willing and able to comply with the requirements of the REMS® program.

          -  Females of reproductive potential must adhere to the scheduled pregnancy testing as
             required in the Revlimid REMS® program.

          -  Females of childbearing potential (FCBP)† must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
             starting lenalidomide with each cycle (prescriptions must be filled within 7 days) and
             must either commit to continued abstinence from heterosexual intercourse or begin TWO
             acceptable methods of birth control, one highly effective method and one additional
             effective method AT THE SAME TIME, at least 28 days before she starts taking
             lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use
             a latex condom during sexual contact with a FCBP even if they have had a successful
             vasectomy.

          -  Able to take prophylactic anticoagulation (aspirin 81 or 325 mg/daily or, for patients
             intolerant to ASA, warfarin or low molecular weight heparin).

        Exclusion Criteria:

          -  Disease progression after stopping corticosteroids as defined as the appearance of a
             detectable serum or urine M-spike, or an absolute increase of &gt;10 mg/dl between
             involved and uninvolved light chains, in the absence of measurable serum or urine
             M-protein .

          -  Patients with a known diagnosis of POEMS syndrome, plasma cell leukemia, CNS
             involvement, non-secretory myeloma and amyloidosis

          -  High-risk myeloma defined by presence of at least one of the following defining
             features on initial diagnostic, or most recent bone marrow biopsy:

          -  High risk chromosomal translocations by FISH: t(4;14), t(14;16), t(14;20),

          -  del(17p), del(1p), amplification 1q.;

          -  MyPRS GEP-70 high risk signature either from diagnosis or at time of registration for
             the study;

          -  LDH &gt; 300 U/L at diagnosis;

          -  Relapse from prior therapy within 12 months.

          -  HIV disease, active infection requiring treatment with antibiotics, anti-fungal or
             anti-viral agents within 2 weeks of enrollment would be excluded from the study.

          -  Patients who have participated in any clinical trial, within the last four weeks,
             which involved an investigational drug.

          -  History of an active malignancy other than myeloma

          -  Autoimmune disease requiring active treatment.

          -  Known contra-indication to any component of allogeneic myeloma vaccine

          -  History of an allogeneic transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Syed A Ali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Syed A Ali, MD</last_name>
    <phone>443-287-7104</phone>
    <email>sali35@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Syed A Ali, MD</last_name>
      <phone>443-287-7104</phone>
      <email>sali35@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lenalidomide</keyword>
  <keyword>M-spike negative</keyword>
  <keyword>GVax</keyword>
  <keyword>GM-CSF secreting myeloma vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

